Dulaglutide; GLP-1 receptor agonist; clinical trial; insulin secretion; once weekly injection; therapy; type 2 diabetes
Abstract :
[en] INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are injectable agents used for the treatment of hyperglycemia in type 2 diabetes. The interest for this pharmacological class is rising with the development of once weekly compounds and the demonstration of a potential reduction in cardiorenal outcomes. Areas covered: The paper describes the main pharmacokinetic/pharmacodynamic characteristics of dulaglutide, a new once-weekly GLP-1 RA. Dulaglutide was extensively investigated in the phase-3 AWARD program, which demonstrated its safety and efficacy when compared to placebo or active glucose-lowering agents in patients treated with diet alone, metformin or sulfonylurea monotherapy, oral dual therapies and basal insulin. In both Caucasian and Japanese patients, comparative trials showed better glucose control with dulaglutide, with a minimal risk of hypoglycemia and weight loss, but at the expense of an increased dropout rate due to side effects, mostly transient gastrointestinal disturbances. Dulaglutide proved its non-inferiority versus liraglutide and the safety and tolerance profile is similar to that of other GLP-1 RAs. Expert opinion: The once-weekly formulation and the combined positive effects on both glucose control and weight improves patient satisfaction despite nausea. Dulaglutide must prove its capacity to reduce cardiovascular and diabetic complications in the ongoing prospective REWIND trial.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Polonsky KS., The past 200 years in diabetes. N Engl J Med. 2012;367:1332–1340.
Banting FG, Best CH, Collip JB, et al. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12:141–146.
Pettus J, Santos Cavaiola T, Tamborlane WV, et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016;32:478–496.
Johnson IS. Human insulin from recombinant DNA technology. Science. 1983;219:632–637.
Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174–183.
Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s - Achievements and future developments. Drugs. 1997;54:355–368.
Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs. 1998;55:225–236.
Scheen AJ. A review of gliptins for 2014. Exp Opin Pharmacother. 2015;16:43–62.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015:a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–442.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary. Endocr Pract. 2016;22:84–113.
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742.
Potts JE, Gray LJ, Brady EM, et al. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes:a systematic review and mixed treatment comparison meta-analysis. Plos One. 2015;10:e0126769.
Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24:15–30.
Barnett AH. Exenatide. Drugs of Today. 2005;41:563–578.
Vilsboll T. Liraglutide:a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs. 2007;16:231–237.
Vilsboll T, Knop FK. Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus. Biodrugs. 2008;22:251–257.
Malone J, Trautmann M, Wilhelm K, et al. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2009;18:359–367.
Zaccardi F, Htike ZZ, Webb DR, et al. Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments:a systematic review and network meta-analysis. Ann Intern Med. 2016;164:102–113.
Polonsky WH, Fisher L, Hessler D, et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13:144–149.
Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31:1119–1133.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
Sanford M. Dulaglutide:first global approval. Drugs. 2014;74:2097–2103.
Kuritzky L, Umpierrez G, Ekoe JM, et al. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med. 2014;126:60–72.
Thompson AM, Trujillo JM. Dulaglutide:the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015;49:351–359.
Scheen AJ. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Rev Clin Pharmacol. 2016;9:385–399.•• This narrative review summarizes the most important results reported with dulaglutide in the AWARD program and in Japanese trials.
Burness CB, Scott LJ. Dulaglutide:a review in type 2 diabetes. Biodrugs. 2015;29:407–418.
Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287–296.
European Medicines Agency. Assessment report:Trulicity (dulaglutide). 2014 [cited published on line;doi; Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002825/WC500179473.pdf (latest access February3, 2017)
Barrington P, Chien JY, Tibaldi F, et al. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab. 2011;13:434–438.
Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:426–433.
Geiser JS, Heathman MA, Cui X, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes:analyses of data from clinical trials. Clin Pharmacokinet. 2016;55:625–634.• This paper summarizes the pharmacokinetics characteristics of dulaglutide from combined phase 2 and phase 3 studies in patients with T2D.
European Medicines Agency. Trulicity:summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002825/WC500179470.pdf (latest access February 3, 2017)
Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015;54:1–21.
Grunberger G, Chang A, Garcia Soria G, et al. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes:dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29:1260–1267.
Terauchi Y, Satoi Y, Takeuchi M, et al. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes:dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocr J. 2014;61:949–959.
Umpierrez GE, Blevins T, Rosenstock J, et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes:the EGO study. Diabetes Obes Metab. 2011;13:418–425.
Umpierrez G, Tofe Povedano S, Perez Manghi F, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168–2176.• A study demonstrating that dulaglutide (both 0.75 and 1.50 mg once weekly) is superior to metformin in patients with T2D treated with diet.
Mari A, Del Prato S, Ludvik B, et al. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic beta-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:834–839.
Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37:2149–2158.• A study demonstrating the superiority of dulaglutide (both 0.75 and 1.50 mg once weekly) compared to sitagliptin 100 mg in metformin-treated patients.
Loghin C, De La Peña A, Cui X, et al. Gastric emptying effects of dulaglutide in patients with type 2 diabetes mellitus. Abstract presented at the 23rd Annual Scientific & Clinical Congress of the American Association of Clinical Endocrinologists, Las Vegas, May 19, 2014.
Jendle J, Grunberger G, Blevins T, et al. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes:a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016;32:776–790.• This meta-analysis summarizes these results from the six completed AWARD studies and concludes that dulaglutide is an effective treatment for T2D, with an acceptable tolerability and safety profile.
Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6):a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349–1357.• A study demonstrating the non-inferiority of dulaglutide 1.5 mg once weekly with liraglutide 1.8 mg once daily in metformin-treated patients
Dungan KM, Weitgasser R, Perez Manghi F, et al. A 24-week study to evaluate the efficacy and safety of once weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab. 2016;18:475–482.• This trial demonstrates the favorable benefit/risk profile of dulaglutide 1.5 mg once weekly when added to glimepiride monotherapy.
Giorgino F, Benroubi M, Jh S, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38:2241–2249.• A study demonstrating the superiority of dulaglutide 1.5 mg once weekly compared to basal insulin glargine in patients on dual oral therapy.
Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159–2167.• A study demonstrating the superiority of dulaglutide (both 0.75 and 1.50 mg once weekly) compared to exenatide 10 µg twice daily as add-on therapy in T2D patients.
Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4):a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385:2057–2066.• A study demonstrating the superiority of dulaglutide (both 0.75 and 1.50 mg once weekly) compared to basal insulin glardine in T2D patients treated with prandial insulin lispro.
Weinstock RS, Guerci B, Umpierrez G, et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5):a randomized, phase III study. Diabetes Obes Metab. 2015;17:849–858.• An extension study showing that 0.75 mg and 1.5 mg dulaglutide doses provided superior glycaemic control versus sitagliptin at 104 weeks, with acceptable safety.
Boustani MA, Pittman I, Yu M, et al. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged >/=65 and <65 years. Diabetes Obes Metab. 2016;18:820–828.
Davidson JA, Manghi FP, Yu M, et al. Efficacy and safety of dulaglutide in Hispanic/Latino patients with type 2 diabetes in the AWARD clinical program. Endocr Pract. 2016;22:1406–1414.
Grunberger G, Forst T, Fernández Landó L, et al. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide. Diabet Med. 2016;33:391–394.
Wysham C, Guerci B, D’Alessio D, et al. Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:1138–1142.
DeFronzo RA, Stonehouse AH, Han J, et al. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies:a meta-analysis of randomized clinical trials. Diabet Med. 2010;27:309–317.
Umpierrez GE, Pantalone KM, Kwan AY, et al. Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment. Diabetes Obes Metab. 2016;18:615–622.
Dungan KM, Raz I, Skrivanek Z, et al. Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme. Diabetes Obes Metab. 2016;18:49–55.
Jendle J, Testa MA, Martin S, et al. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro:an AWARD-4 substudy. Diabetes Obes Metab. 2016;18:999–1005.
Yu M, Van Brunt K, Varnado OJ, et al. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide:data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016;18:419–424.
Kim YG, Hahn S, Oh TJ, et al. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians:a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:900–909.
Miyagawa JI, Odawara M, Takamura T, et al. Once weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes:a 26-week randomised phase 3 study. Diabetes Obes Metab. 2015;17:974–983.
Araki E, Inagaki N, Tanizawa Y, et al. Efficacy and safety of once weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once daily insulin glargine in Japanese patients with type 2 diabetes:a randomised, open-label, phase 3, non-inferiority study. Diabetes Obes Metab. 2015;17:994–1002.
Odawara M, Miyagawa J, Iwamoto N, et al. Once weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases HbA1c compared with once daily liraglutide in Japanese patients with type 2 diabetes:52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab. 2016;18:249–257.
Onishi Y, Oura T, Nishiyama H, et al. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. Endocr J. 2016;63:263–273.
Inagaki N, Araki E, Oura T, et al. The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:1279–1282.
Karagiannis T, Liakos A, Bekiari E, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes:a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2015;17:1065–1074.• A meta-analysis showing that once-weekly GLP-1 RAs, including dulaglutide, are a convenient, effective, and safe therapeutic option in T2D patients.
Zhang L, Zhang M, Zhang Y, et al. Efficacy and safety of dulaglutide in patients with type 2 diabetes:a meta-analysis and systematic review. Sci Rep. 2016;6:18904.•• A meta-analysis showing that the use of dulaglutide as a monotherapy or an add-on therapy is effective and safe for patients with T2D.
Fahrbach JL, Fu H, Shurzinske L, et al. Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg. Int J Clin Pract. 2016;70:218–221.
Milicevic Z, Anglin G, Harper K, et al. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide. Diabetes Obesity Metab. 2016;18:533–536.
Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs–FDA and EMA assessment. N Engl J Med. 2014;370:794–797.
Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64:731–737.
Ferdinand KC, Botros FT, Atisso CM, et al. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes:a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2016;15:38.• This meta-analysis of nine RCTs suggests that dulaglutide does not increase but may reduce the risk of major cardiovascular events in T2D patients.
U.S. National Institutes of Health. Researching cardiovascular events with a weekly incretin in diabetes (REWIND). https://clinicaltrials.gov/ct2/show/NCT01394952 (latest access Feb 03, 2017)
Tuttle KR, Dwight Mckinney T, Davidson JA, et al. The effects of once weekly dulaglutide on kidney function in patients with type 2 diabetes in phase 2 and 3 clinical trials. Diabetes Obes Metab 2016;Oct. 21. doi:10.1111/dom.12816. [Epub ahead of print].
Purnell TS, Joy S, Little E, et al. Patient preferences for noninsulin diabetes medications:a systematic review. Diabetes Care. 2014;37:2055–2062.
Gelhorn HL, Poon JL, Davies EW, et al. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naive type 2 diabetes patients in the UK. Patient Prefer Adherence. 2015;9:1611–1622.
Gelhorn HL, Bacci ED, Poon JL, et al. Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan. Patient Prefer Adherence. 2016;10:1337–1348.
Anderson JE, Thieu VT, Boye KS, et al. Dulaglutide in the treatment of adult type 2 diabetes:a perspective for primary care providers. Postgrad Med. 2016;128:810–821.
Thompson AM, Trujillo JM. Advances in the treatment of type 2 diabetes:impact of dulaglutide. Diabetes Metab Syndr Obes. 2016;9:125–136.
Amblee A. Mode of administration of dulaglutide:implications for treatment adherence. Patient Prefer Adherence. 2016;10:975–982.
Matfin G, Van Brunt K, Zimmermann AG, et al. Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naive patients with type 2 diabetes. J Diabetes Sci Technol. 2015;9:1071–1079.
Hauber AB, Nguyen H, Posner J, et al. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Curr Med Res Opin. 2016;32:251–262.
Pétré B, Scheen AJ, Ziegler O, et al. Body image discrepancy and subjective norm as mediators and moderators of the relationship between body mass index and quality of life. Patient Prefer Adherence. 2016;10:2261–2270.
Noh RM, Graveling AJ, Frier BM. Medically minimising the impact of hypoglycaemia in type 2 diabetes:a review. Expert Opin Pharmacother. 2011;12:2161–2175.
Reaney M, Yu M, Lakshmanan M, et al. Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide:data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab. 2015;17:896–903.
Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists:a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6:19–28.
Scheen AJ. Which incretin-based therapy for type 2 diabetes?. Lancet. 2014;384:1325–1327.
Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6):a randomised, open-label study. Lancet. 2013;381:117–124.
Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7):a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289–297.
Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes:a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240–1250.
Yabe D, Kuwata H, Usui R, et al. Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management:assessment of composite end-points. Curr Med Res Opin. 2015;31:1267–1270.
Ross SA. A multiplicity of targets:evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes. Curr Med Res Opin. 2015;31:125–135.
Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes:a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14:77–82.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
Monami M, Dicembrini I, Nardini C, et al. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk:a meta-analysis of randomised clinical trials. Diabetes Obes Metabol. 2014;16:38–47.
Fisher M, Petrie MC, Ambery PD, et al. Cardiovascular safety of albiglutide in the Harmony programme:a meta-analysis. Lancet Diabetes Endocrinol. 2015;3:697–703.
Scheen AJ. Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists. Lancet Diabetes Endocrinol. 2015;3:667–669.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015:a patient-centered approach:update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–336.
Scheen AJ. Precision medicine:the future in diabetes care?. Diabetes Res Clin Pract. 2016;117:12–21.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
